Viveve Medical (Viveve Medical) EBIT : $-21.23 Mil (TTM As of Sep. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Viveve Medical EBIT?

Viveve Medical's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2022 was $-4.68 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2022 was $-21.23 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Viveve Medical's annualized ROC % for the quarter that ended in Sep. 2022 was -216.16%. Viveve Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -1,765.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Viveve Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was 92,313.04%.

Viveve Medical EBIT Historical Data

The historical data trend for Viveve Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viveve Medical EBIT Chart

Viveve Medical Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT

Get a 7-Day Free Trial

-33.79

-44.95

-37.55

-20.62

-20.77

Viveve Medical Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EBIT	Get a 7-Day Free Trial															-5.57	-5.99	-5.49	-5.06	-4.68

Competitive Comparison of Viveve Medical's EBIT

For the Medical Devices subindustry, Viveve Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viveve Medical's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Viveve Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Viveve Medical's EV-to-EBIT falls into.

Viveve Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.23 Mil.

Viveve Medical (OTCPK:VIVE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Viveve Medical's annualized ROC % for the quarter that ended in Sep. 2022 is calculated as:

	ROC % (Q: Sep. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2022 )	+	Invested Capital (Q: Sep. 2022 ))	/ count )
=	-18.648 * ( 1 - 0% )	/	( (8.411	+	8.843)	/ 2 )
=	-18.648	/	8.627
=	-216.16 %

where

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	15.488	-	3.851	-	( 9.431	-	max(0, 10.012	-	13.238	+	9.431	))
=	8.411

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	12.154	-	4.544	-	( 5.907	-	max(0, 10.837	-	9.604	+	5.907	))
=	8.843

Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Viveve Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2022		Q: Sep. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-18.736	/	( ( (1.114 + max(-0.508, 0))	+	(1.009 + max(-1.259, 0)) )	/	2 )
=	-18.736	/	( ( 1.114	+	1.009 )	/	2 )
=	-18.736	/	1.0615
=	-1,765.05 %

where Working Capital is:

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.801	+	1.599	+	1.407)	-	(3.851	+	0.464	+	0)
=	-0.508

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.86	+	1.615	+	1.222)	-	(4.544	+	0.412	+	-1.7763568394003E-15)
=	-1.259

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Viveve Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2022 )
	=	-21.232	/	-0.023
	=	92,313.04 %

Viveve Medical EBIT Related Terms

Thank you for viewing the detailed overview of Viveve Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Viveve Medical (Viveve Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Viveve Medical Inc (OTCPK:VIVE) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

345 Inverness Drive South, Building B, Suite 250, Englewood, CO, USA, 80112

Website

https://www.viveve.com

Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.

Executives

Presnell Sharon Collins	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Wilmot B. Harkey	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc	10 percent owner	130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Karen L. Zaderej	director	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Steven L Basta	director	1875 S GRANT STREET SUITE 110, SAN MATEO CA 94402
Scott Durbin	officer: Chief Financial Officer	PO BOX 376, ANN ARBOR MI 48106
James G. Atkinson	officer: CBO & President	150 COMMERCIAL STREET, SUNNYVALE CA 94086
Patricia Scheller	director, officer: CEO and Director	150 COMMERCIAL STREET, SUNNYVALE CA 94086
Jon M Plexico	director, 10 percent owner	16430 N SCOTTSDALE RD 450, SCOTTSDALE AZ 85254
Stonepine Capital Management, Llc	director, 10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Timothy P Lynch	director, 10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Daniel Janney	director, 10 percent owner	PO BOX 7414, JACKSON WY 83002